ReviewJournal of clinical medicine2025
State of the Art of Primary PCI: Present and Future.
Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Coronary microvascular injury detection and prediction after successful primary percutaneous coronary intervention: non-invasive assessment using single photon emission tomography myocardial perfusion imaging.Annals of nuclear medicine · 2026Article
- Extracellular Traps in Coronary Thrombus Aspirates from Patients with ST-Elevation Myocardial Infarction.International journal of molecular sciences · 2026Article
- Inflammation-Mediated Mechanisms of Arrhythmias After Acute Myocardial Infarction.Reviews in cardiovascular medicine · 2026Review
- Prognostic Value of the Osaka Prognostic Score for One-Year Mortality in Patients with ST-Segment Elevation Myocardial Infarction: A Retrospective Observational Cohort Study.Journal of clinical medicine · 2026Article
- Complete versus culprit only revascularization in young STEMI patients with multivessel disease.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2026Article
- Insulin or Dapagliflozin Potentially Improves Microcirculatory Dysfunction or INOCA Related to Culprit Vessels in Diabetic Patients With STEMI After DCB Therapy During Long-Term Follow-Up.Journal of diabetes · 2026Observational
- Predictors of Impaired Reperfusion in ST-Elevation Myocardial Infarction Treated with Primary PCI: Preliminary Results from COMA.NET Project.Diagnostics (Basel, Switzerland) · 2026Article
- From "Rational Agent" to "Bounded Rationality": A Qualitative Study of Decision-Making Biases in Exercise Behavior Among Post-PCI Patients with Coronary Heart Disease.Patient preference and adherence · 2026Article
- Predictive value of HPSE for major adverse cardiovascular events in patients with ST-segment elevation myocardial infarction.Frontiers in cardiovascular medicine · 2026Article
- Beta-blockers after myocardial infarction with preserved or mildly reduced ejection fraction: existing evidence, knowledge gaps, and an EF-stratified framework.Frontiers in pharmacology · 2026Article
- Association Between the Atherogenic Index of Plasma and the Occurrence of Slow Flow/No-Reflow in Patients With Acute Myocardial Infarction Undergoing Emergency Percutaneous Coronary Intervention.Cardiology research and practice · 2026Article
- Article
- [Evaluation of coronary microvascular dysfunction for assessing prognosis of ST-segment elevation acute myocardial infarction following reperfusion therapy: insights from QFR-AMR].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025Article
- Association between insulin resistance and coronary microcirculatory function and adverse cardiovascular events after PCI in non-diabetic STEMI patients.Frontiers in cardiovascular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary percutaneous coronary intervention (PCI) has revolutionized the management of ST-elevation myocardial infarction (STEMI), markedly improving patient outcomes. Despite technological advancements, pharmacological innovations, and refined interventional techniques, STEMI prognosis remains burdened by a persistent incidence of cardiac death and heart failure (HF), with mortality rates plateauing over the last decade. This review examines current practices in primary PCI, focusing on critical factors influencing patient outcomes. Moreover, it explores future developments, emphasizing the role of microvascular dysfunction-a critical but often under-recognized contributor to adverse outcomes, including incident HF and mortality, and has emerged as a key therapeutic frontier. Strategies aimed at preserving microvascular function, mitigating ischemia-reperfusion injury, and reducing infarct size are discussed as potential avenues for improving STEMI management. By addressing these challenges, the field can advance toward more personalized and effective interventions, potentially breaking the current deadlock in mortality rates and improving longer-term prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.